ClinicalTrials.gg
TerminatedNCT06522035Updated Apr 13, 2026

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

A Phase 1 interventional study of Allocetra in Arthritis, Psoriatic, sponsored by Enlivex Therapeutics Ltd.. Terminated at 4 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Enlivex Therapeutics Ltd. · Phase 1, Interventional, and Treatment

Why this study was terminated
reprioritization

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Arthritis, Psoriatic with a site in Israel — 4 open to participants now, 11 under way, 7 of them phase 3. Arthritis, Psoriatic · Israel.

Enrollment
20th of 20
5 · median 535
Started
2024
with 1 other
Phase 1
Only one
of the 25
Registered
21st of 25
by date
Lead sponsor
1 of 25
Enlivex Therapeutics Ltd.

Among the 25 studies in Arthritis, Psoriatic with a site in Israel, this one is the 20th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 1, and was the 21st registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

4 of the 25 studies in Arthritis, Psoriatic with a site in Israel are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Arthritis, Psoriatic with a site in Israel, or all of them as a file.
02

Study summary

This is an open label study to evaluate the safety and initial efficacy of intra-articular administration of Allocetra in patients with Psoriatic Arthritis (PsA).

Read the detailed description

Psoriatic Arthritis (PsA) is a prevalent chronic inflammatory disease that mainly affects the synovial joints, and leads to inflammatory arthritis, in addition to skin manifestations. If left untreated, inflammatory arthritis leads to joint damage and deformities.

Allocetra is an immunomodulatory cell-based therapy consisting of allogeneic peripheral blood mononuclear cells that have been modified to be engulfed by macrophages and reprogram them into their homeostatic state.

As macrophages play a crucial role in the initiation of PsA immunopathogenesis, they are considered an emerging target for PsA treatment.

This study will assess the safety of Allocetra injection to the joint (knee, elbow or ankle) in patients with PsA, and evaluate the preliminary responses to treatment.

03

Conditions studied

  • Arthritis, Psoriatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with PsA.
  2. Stage 1 patients:

    At least one joint resistant to standard PsA treatments and on a stable dose of approved PsA treatment for at least 3 months prior to treatment.

  3. Stage 2 patients:

    At least one symptomatic joint following attempt of intra-articular injection of , with insufficient response.

  4. Acceptable blood tests- Complete Blood Count (CBC), electrolytes, adequate renal function, adequate liver function.

Exclusion criteria

Exclusion Criteria:

  1. Prior intra-articular injection to the target joint of , hyaluronate or other drugs within 3 months prior to treatment.
  2. Any significant injury to the target joint within the 6 months prior to treatment, or any surgery to the target joint within the 12 months prior to treatment.
  3. Findings of acute fractures, severe loss of bone density, chondrocalcinosis and/or severe bone or joint deformity in the target joint.
  4. Evidence of active local infection in the target joint.
  5. Concomitant rheumatic, inflammatory or disease other than PsA.
  6. Other limb pain of unknown etiology.
  7. Any evidence of active infection.
  8. Major medical condition as detailed in the protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Stage 1

    Stage 1 will include patients who have been treated with standard PsA therapies, and are insufficiently responsive to treatment in one or more involved joints.

    Drug: Allocetra

  • Experimental
    Stage 2

    Stage 2 will include patients with oligoarticular PsA (1-4 joints involved), who have received at least one injection of corticosteroids to the target joint with insufficient response.

    Drug: Allocetra

Interventions

  • DrugAllocetra

    Intra-articular injecton of Allocetra into the target joint.

06

What researchers measure

Primary outcomes

  1. Primary outcome

    Number and severity of AEs, SAEs and injection reactions following treatment

    Time frame: 12 months

Secondary outcomes

  1. Patient reported pain Numeric Rating Scale (NRS) in the target joint.

    Evaluation of change from baseline in patient reported pain Numeric Rating Scale (NRS) in the target joint.

    Time frame: 3 months, 6 months and 12 months.

Other outcomes

  1. Exploratory outcome- assessment of change from baseline in Psoriasis Area and Severity Index (PASI).

    Time frame: 12 months

  2. Exploratory outcome- assessment of change from baseline in Disease Activity in Psoriatic Arthritis (DAPSA) score.

    Time frame: 12 months

07

Study locations

4 sites
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • Carmel Medical Center
    Haifa, 3436212, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Tel Aviv Sourasky Medical Center - Ichilov
    Tel Aviv, 6423906, Israel
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Oct 2025, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2024
First posted
Jul 26, 2024
StartActual
Aug 1, 2024
Primary completionActual
Oct 20, 2025
CompletionActual
Apr 8, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06522035
Lead sponsor
Enlivex Therapeutics Ltd.
Responsible party
Sponsor
First posted
Jul 26, 2024
Start date
Aug 1, 2024
Primary completion
Oct 20, 2025
Completion
Apr 8, 2026
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion